New hope for tough lung cancer: onvansertib trial targets relapsed small cell
NCT ID NCT05450965
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a drug called onvansertib in about 37 people with small cell lung cancer that has come back or hasn't responded to chemotherapy. Onvansertib works by blocking a protein that cancer cells need to grow and repair themselves. The main goal is to see if the drug can shrink tumors, while also checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Onvansertib (a drug that blocks a protein called PLK1, which helps cancer cells grow and repair themselves)
What this could lead to
If successful, this could provide a new treatment option for people with small cell lung cancer whose disease has returned or who cannot tolerate standard chemotherapy.
What could go wrong
This is an early phase 2 trial with only 37 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
ACTIVE_NOT_RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
Contact
Contact